TransMedics Group, Inc. (TMDX)
| Market Cap | 3.49B |
| Revenue (ttm) | 605.49M |
| Net Income (ttm) | 190.29M |
| Shares Out | 34.54M |
| EPS (ttm) | 4.87 |
| PE Ratio | 20.76 |
| Forward PE | 41.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,930,420 |
| Open | 106.70 |
| Previous Close | 108.12 |
| Day's Range | 100.50 - 106.88 |
| 52-Week Range | 88.50 - 156.00 |
| Beta | 2.08 |
| Analysts | Buy |
| Price Target | 148.22 (+46.51%) |
| Earnings Date | May 5, 2026 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $148.22, which is an increase of 46.51% from the latest price.
News
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinic...
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics Group Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management outlined plans to deepen integration into the U.S. transplant ecosystem, highlighted robust clinical trial progress, and detailed ongoing European expansion and operational improvements. Regulatory decisions on further integration are expected by 2027, with significant growth anticipated in kidney and international markets.
TransMedics Group Transcript: TD Cowen 46th Annual Health Care Conference
OCS Kidney is positioned to address rising DGF rates and low kidney utilization, with a late 2025/early 2027 rollout. Next-gen OCS devices will drive margin expansion, while ongoing trials and regulatory changes offer growth opportunities. International expansion, especially in Europe, is a key focus.
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 37% revenue growth, strong operating leverage, and robust cash flow. 2026 guidance targets 20–25% revenue growth, supported by clinical adoption, new programs, and international expansion, despite near-term margin pressures.
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Group Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company showcased strong growth in organ transplant volumes, driven by its OCS platform and integrated logistics. Key milestones include FDA approval for new clinical trials, record-high organ utilization rates, and ambitious expansion plans in the U.S. and Europe. Financial targets include a 60% gross margin and 30% operating margin by 2028.
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts
ANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a lo...
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group Transcript: Piper Sandler 37th Annual Healthcare Conference
Machine perfusion adoption is expanding, with major data publications expected in 2026 and a target of 10,000 transplants by 2028. New clinical trials for heart and lung are underway, and kidney represents a significant future growth area. Operating margin is targeted at 30% by 2028.
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
TransMedics Group Earnings Call Transcript: Q3 2025
Q3 2025 saw 32% year-over-year revenue growth, margin expansion, and strong cash generation, with all organ segments contributing. Guidance for 2025 was raised, international expansion is underway, and new clinical programs are set to drive further growth.
TransMedics Reports Third Quarter 2025 Financial Results
ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion techn...